TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11505347

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol (plasma target concentration, 2 to 3 microg x mL; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) of propofol (2.5 to 3.5 mg/kg/hr; n = 10)
Number of subjects: 20
Study: 9262266

Group type: EXPERIMENTAL
Intervention: Ultrashort gonadotrophin-releasing hormone agonist protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified suppression gonadotrophin-releasing hormone agonist protocol
Number of subjects: 60
Study: 8486173

Group type: COMPARATOR
Intervention: 4 or 8 mg of oral E2 and vaginal ultrasound (US) daily until endometrial thickness > or = 6 mm with a triple‐line pattern
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: US monitoring of endometrial development during estrogen (E) administration
Number of subjects: 12
Study: 3567045

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2547137

Group type: EXPERIMENTAL
Intervention: Cyclic oestradiol valerate plus cyproterone acetate (E2V + CPA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Continuous 17 beta-oestradiol plus norethisterone acetate (E2 + NETA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Withdrawal of hormone therapy
Number of subjects: 86
Study: 30863080

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month (PP3M)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month (PP1M)
Number of subjects: 995
Study: 28486381

Group type: EXPERIMENTAL
Intervention: Concurrent Foley and oxytocin
Number of subjects: 323

Group type: COMPARATOR
Intervention: Foley followed by oxytocin
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 323
Study: 25797871

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 20

Group type: COMPARATOR
Intervention: CERA (Epoetin Beta pegol)
Number of subjects: 20
Study: 23313969

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ramosetron plus Dexamethasone (8 mg + 0.3 mg)
Number of subjects: 76
Study: 21306837

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus feedback and skills building (MI+)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Video information plus debriefing (Video+)
Number of subjects: 54
Study: 19634969

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 180
Study: 16761228

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 18 microg once daily
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 1639
Study: 15793055

Group type: EXPERIMENTAL
Intervention: Low prime volume pump (LPVP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal prime volume CPB (Group N)
Number of subjects: 14
Study: 11213955

Group type: EXPERIMENTAL
Intervention: Nausea and vomiting
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Irritability
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Decreased level of consciousness (LOC)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Erythema
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Bulging fontanelle
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Loss of developmental milestones (late encounters)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Decreased LOC (late encounters)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Shunt score (early encounters)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Shunt score (late encounters)
Number of subjects: 431
Study: 9200849

Group type: EXPERIMENTAL
Intervention: Exposure to pseudocumene, mesitylene, or hemimellitene at concentrations ranging from 5 to 150 mg/m3 air.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exposure to TMB at various concentrations.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TMB exposure and its metabolites in biological fluids.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Proposed biological exposure limit (BEL) for TMB.
Number of subjects: 8
Study: 8197906

Group type: EXPERIMENTAL
Intervention: Biodegradable pins with x-ray opaque markers (Polypin)
Number of subjects: 57
Study: 2906453

Group type: EXPERIMENTAL
Intervention: 10 mg mifentidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg mifentidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30623268

Group type: EXPERIMENTAL
Intervention: Spinal orthosis
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Equipment training
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 28535474

Group type: EXPERIMENTAL
Intervention: Peer Navigator Program (PNP)
Number of subjects: 0
Study: 26256990

Group type: COMPARATOR
Intervention: Control group (ventilation with a tidal volume of 8 mL/kg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PEEP group (ventilation with a tidal volume of 6 mL/kg and PEEP of 8 cm H₂O)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: AR group (alveolar recruitment maneuver followed by PEEP of 8 cm H₂O)
Number of subjects: 99
Study: 22855267

Group type: EXPERIMENTAL
Intervention: Polyurethane foam (PU) with 55% polyethylene glycol (PEG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Collagen
Number of subjects: 2

Group type: COMPARATOR
Intervention: Gelatin
Number of subjects: 2
Study: 20809091

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 18509179

Group type: EXPERIMENTAL
Intervention: Valspodar (PSC 833) 5 mg/kg every 6 hours for 12 doses, paclitaxel 80 mg/m(2), and carboplatin AUC 6 (PC-PSC)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m(2) and carboplatin AUC 6 (PC)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Valspodar (PSC 833) combined with paclitaxel and carboplatin (PC-PSC)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (PC)
Number of subjects: 762
Study: 16781225

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 40 mg TID
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12925096

Group type: EXPERIMENTAL
Intervention: Non-vaccinated children
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Children vaccinated with pertussis toxoid
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 207
Study: 10893651

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg/day
Number of subjects: 211
Study: 8840357

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1900014

Group type: EXPERIMENTAL
Intervention: Hyperventilation to a mean PaCO2 of 3.3 kPa (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normocapnia with a mean PaCO2 of 5.3 kPa (Group II)
Number of subjects: 30
Study: 6131448

Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Crotylbarbital (2 mg/kg)
Number of subjects: 15
Study: 30782716

Group type: EXPERIMENTAL
Intervention: Automated oxygen administration (FreeO2 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (Standard group)
Number of subjects: 0
Study: 29413361

Group type: EXPERIMENTAL
Intervention: DHA+EPA 750mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DHA+EPA 1000mg/day
Number of subjects: 36
Study: 27244706

Group type: EXPERIMENTAL
Intervention: Parent Mentors (PMs)
Number of subjects: 237
Study: 24918373

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo to open-label brodalumab
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Brodalumab groups
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 168
Study: 22851684

Group type: EXPERIMENTAL
Intervention: Simple stenting strategy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Complex stenting strategy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Troponin use in simple stenting strategy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Troponin use in complex stenting strategy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Troponin use overall
Number of subjects: 500
Study: 19902267

Group type: EXPERIMENTAL
Intervention: Combination steroid and mizoribine (MZB) therapy (4-5 mg/kg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Steroid only therapy
Number of subjects: 57
Study: 18304050

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Promethazine 25 mg
Number of subjects: 120
Study: 15749143

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11928179

Group type: EXPERIMENTAL
Intervention: DHEA (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10424380

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel applied by interdental flossing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel applied using individually designed mouth trays
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel applied by a combination of polishing and flossing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Flossing alone
Number of subjects: 21
Study: 8567877

Group type: EXPERIMENTAL
Intervention: BACTEC 9240 Aerobic/F resin bottle
Number of subjects: 520

Group type: COMPARATOR
Intervention: Isolator system
Number of subjects: 520
Study: 2116808

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of gamma‐glutamyl‐L‐dopa (25 micrograms/kg/min) for 10 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dosing of gludopa
Number of subjects: 0
Study: 361362

Group type: EXPERIMENTAL
Intervention: Oral aromatic retinoid (1.0 mg/kg body-weight)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Photochemotherapy alone (Control)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Photochemotherapy with retinoid
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Standard photochemotherapy maintenance treatment
Number of subjects: 134
Study: 31174347

Group type: EXPERIMENTAL
Intervention: Dietary Guideline Index (DGI) applied to weighed food records (WFR)
Number of subjects: 141
Study: 28664834

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 25600572

Group type: EXPERIMENTAL
Intervention: DFP and DFX
Number of subjects: 96

Group type: COMPARATOR
Intervention: DFP and DFO
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 96
Study: 23659394

Group type: EXPERIMENTAL
Intervention: 1 µg/kg dexmedetomidine (Group D(2))
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg dexmedetomidine (Group D(1))
Number of subjects: 87

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 87
Study: 21040180

Group type: EXPERIMENTAL
Intervention: Follow-up phone calls
Number of subjects: 63

Group type: COMPARATOR
Intervention: No phone call (control)
Number of subjects: 63
Study: 18412642

Group type: EXPERIMENTAL
Intervention: High end-tidal carbon dioxide (3-12 kPa)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Normal end-tidal carbon dioxide (3-12 kPa)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low end-tidal carbon dioxide (3-12 kPa)
Number of subjects: 24
Study: 16988273

Group type: EXPERIMENTAL
Intervention: DDM-ME TRAP regimen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DDM-CS regimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 16
Study: 12966663

Group type: EXPERIMENTAL
Intervention: Surgical management with improved perioperative management and advanced cardiopulmonary bypass technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future surgical techniques
Number of subjects: 0
Study: 10985138

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU of retinyl palmitate on study days 1, 4, and 8)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (similar appearance to vitamin A drops)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 130
Study: 1639053

Group type: EXPERIMENTAL
Intervention: Selenium-rich bread (200 micrograms Se) for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-Se bread (control)
Number of subjects: 12
Study: 6375599

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1 day (1.5 g every 8 hours, starting 1 hour before surgery)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cefuroxime 3 days (1.5 g every 8 hours, starting 1 hour before surgery)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 30736770

Group type: EXPERIMENTAL
Intervention: 3D printing model (n = 23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine treatment (n = 25)
Number of subjects: 48
Study: 29781884

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26645159

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection (USGI) of corticosteroids (20mg of methylprednisolone acetate)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional blind injection (CBI) of corticosteroids (20mg of methylprednisolone acetate)
Number of subjects: 114
Study: 24790422

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined (collapsed by group)
Number of subjects: 20
Study: 22448810

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg plus mosapride 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Omeprazole 20 mg alone
Number of subjects: 10
Study: 20429492

Group type: EXPERIMENTAL
Intervention: Story Sharing (StS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Communication Skills
Number of subjects: 0
Study: 17920731

Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA vaccine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16132246

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (initiated on postoperative day 4)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dietary therapy alone (control group)
Number of subjects: 72
Study: 11881315

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) administered orally 12 and 2 hours before surgery, and every 8 hours until the third postoperative day.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ibuprofen treatment).
Number of subjects: 20
Study: 10225548

Group type: EXPERIMENTAL
Intervention: Sanguinarine toothpaste and oral rinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control toothpaste and oral rinse without sanguinarine
Number of subjects: 60
Study: 8942892

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.5 mg/ml)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 72
Study: 1883776

Group type: EXPERIMENTAL
Intervention: 2.4% Methoxyflurane (MOF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Phenol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (MOF)
Number of subjects: 2
Study: 7161115

Group type: EXPERIMENTAL
Intervention: 6 mg of dexamethasone
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 31852676

Group type: EXPERIMENTAL
Intervention: Saying 'Today will be a quiet day'
Number of subjects: 61

Group type: COMPARATOR
Intervention: Refraining from saying 'quiet'
Number of subjects: 61
Study: 27762628

Group type: EXPERIMENTAL
Intervention: 80% power from beginning until the end of treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: First 100 shockwaves at 40% power, then 80% power until the end of treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: First 100 shocks at 40% power, followed by a 3‐minute pause, then 80% power until the end of treatment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: First 100 shocks at 80% power, followed by a 3‐minute pause, then 80% power until the end of treatment
Number of subjects: 320
Study: 27920416

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study: 26905705

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by vaginal misoprostol induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal misoprostol induction only
Number of subjects: 100
Study: 22160450

Group type: EXPERIMENTAL
Intervention: Olive oil meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cream meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both meals (olive oil and cream)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chylomicron-PON1 activity
Number of subjects: 40
Study: 21063138

Group type: EXPERIMENTAL
Intervention: Air-abrasion method (KCP 2000 PLUS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Acid etching method (Vococid)
Number of subjects: 88
Study: 17984842

Group type: EXPERIMENTAL
Intervention: 5 mg FTY720 (Group 1)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 2.5 mg FTY720 (Group 2)
Number of subjects: 271

Group type: COMPARATOR
Intervention: mycophenolate mofetil (MMF; Group 3)
Number of subjects: 271
Study: 15979438

Group type: EXPERIMENTAL
Intervention: IVUS-measured minimum stent diameters
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Predicted stent diameters from manufacturers' compliance charts
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ratio of IVUS to predicted diameters
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: IVUS measurements for different stent sizes
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: IVUS measurements for different stent manufacturers
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Percentage of stents achieving predicted diameters
Number of subjects: 212
Study: 11960300

Group type: EXPERIMENTAL
Intervention: Complete micronutrient-enriched liquid nutrition supplement (125 ml and 0.6 MJ (135 kcal) twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 42
Study: 9864279

Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 42 mg/day transdermal nicotine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 63 mg/day transdermal nicotine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8748047

Group type: EXPERIMENTAL
Intervention: ipsapirone (mean daily dose 19.5 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: lorazepam (mean daily dose 4.2 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 2028089

Group type: EXPERIMENTAL
Intervention: Low similarity tasks with contextual interference during acquisition and retention.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High similarity tasks with contextual interference during acquisition and retention.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transfer trials of a novel movement after retention interval.
Number of subjects: 60
Study: 6118384

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg nebulized)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30608001

Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 53
Study: 28004320

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam
Number of subjects: 1095
Study: 26445141

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS)
Number of subjects: 0
Study: 23374201

Group type: EXPERIMENTAL
Intervention: 8-week Iyengar yoga program (2 x 90-min classes and 5 x 30-min home sessions per week)
Number of subjects: 42
Study: 21340401

Group type: EXPERIMENTAL
Intervention: Human rhinovirus (HRV) detection
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Human metapneumovirus (hMPV) detection
Number of subjects: 47

Group type: COMPARATOR
Intervention: Influenza A/B and RSV detection
Number of subjects: 47
Study: 19729344

Group type: EXPERIMENTAL
Intervention: 250 microg interferon beta‐1b
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: 500 microg interferon beta‐1b
Number of subjects: 2244

Group type: COMPARATOR
Intervention: 20 mg glatiramer acetate
Number of subjects: 2244
Study: 17544884

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15383081

Group type: EXPERIMENTAL
Intervention: Single incremental cycle exercise test with respiratory gas exchange measurement.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeatability of the incremental test over 5-6 weeks.
Number of subjects: 0
Study: 11685417

Group type: EXPERIMENTAL
Intervention: Magstim 200
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Magstim Super Rapid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both stimulators
Number of subjects: 2
Study: 9624645

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 682 Torr
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 632 Torr
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 566 Torr
Number of subjects: 28